Soleno Therapeutics, Inc.
General ticker "SLNO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.9B (TTM average)
Soleno Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -26.6%.
Estimated limits based on current volatility of 1.2%: low 51.91$, high 52.84$
Factors to consider:
- Total employees count: 92 (+178.8%) as of 2024
- Top business risk factors: Lack of approved products, Dependence on DCCR, Regulatory and compliance, Operational and conduct risks, High R&D costs
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [29.82$, 66.77$]
- 2026-12-31 to 2027-12-31 estimated range: [25.13$, 57.45$]
Financial Metrics affecting the SLNO estimates:
- Negative: with PPE of 209.0 at the end of fiscal year the price was high
- Positive: 7.68 < Operating profit margin, % of 7.85
- Negative: Inventory ratio change, % of 7.31 > 0.80
- Negative: -0.15 < Industry inventory ratio change (median), % of 0
- Positive: Interest expense per share per price, % of 0.21 <= 0.73
- Positive: 0.07 < Operating cash flow per share per price, % of 1.83
- Negative: Investing cash flow per share per price, % of -7.90 <= -4.45
- Positive: Shareholder equity ratio, % of 79.83 > 64.25
- Negative: Return on assets ratio (scaled to [-100,100]) of 3.57 <= 6.12
- Negative: negative Industry operating income (median)
Short-term SLNO quotes
Long-term SLNO plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $190.41MM |
| Operating Expenses | $41.38MM | $187.67MM | $175.46MM |
| Operating Income | $-41.38MM | $-187.67MM | $14.95MM |
| Non-Operating Income | $2.40MM | $11.82MM | $5.94MM |
| Interest Expense | $0.00MM | $0.23MM | $5.48MM |
| R&D Expense | $25.19MM | $78.57MM | $40.63MM |
| Income(Loss) | $-38.99MM | $-175.85MM | $20.89MM |
| Profit(Loss)* | $-38.99MM | $-175.85MM | $20.89MM |
| Stockholders Equity | $157.51MM | $245.11MM | $450.12MM |
| Inventory | $0.00MM | $0.00MM | $15.02MM |
| Assets | $180.69MM | $330.97MM | $563.83MM |
| Operating Cash Flow | $-24.94MM | $-69.10MM | $46.80MM |
| Capital expenditure | $0.00MM | $0.22MM | $0.07MM |
| Investing Cash Flow | $0.00MM | $-225.68MM | $-201.78MM |
| Financing Cash Flow | $180.02MM | $213.03MM | $137.16MM |
| Earnings Per Share** | $-2.36 | $-4.38 | $0.39 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.